Compare Halliburton Company (HAL) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halliburton Company vs IDEXX Laboratories, Inc. — how do they compare? Halliburton Company trades at $33.8 (market cap $28.03B), while IDEXX Laboratories, Inc. trades at $588.36 (market cap $46.93B). The key difference: IDEXX Laboratories, Inc. is the larger of the two by market cap, and Halliburton Company pays a 2.02% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| HAL | IDXX | |
|---|---|---|
Market Cap | $28.03B | $46.93B |
Sector | Energy | Health |
52-Week High | $42.98 | $766.68 |
52-Week Low | $20.50 | $526.44 |
Enterprise Value | $34.18B | $47.83B |
Dividend Yield | 2.02% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Halliburton (HAL) trades at $31.89, down 1.91% amid technical bearish signals despite strong fundamentals. The company reported Q2 2026 EPS of $0.55, beating estimates, with revenue growth driven by international contracts. Valuation metrics remain attractive with P/E of 16.7 and P/S of 1.2, while analyst consensus shows 73% buy ratings with a $43.60 price target. Recent news highlights contract wins in Kuwait and Australia, though Middle East volatility presents near-term headwinds.
HAL offers value with solid earnings momentum and global expansion, but faces execution risks from geopolitical tensions and oil market volatility. The stock's current discount to analyst targets presents opportunity, though technical weakness suggests cautious entry timing. Long-term growth prospects remain intact through technology leadership and international contract pipeline.
IDEXX Laboratories trades at $586.67, down 0.56% on the day, with strong technical momentum showing bullish moving averages and key resistance at $590. The company demonstrates robust fundamentals with Q2 2026 EPS of $4.27 beating estimates by 8.4% and full-year guidance raised to $14.69-14.94. Revenue growth accelerated to 10% year-over-year, supported by 9% organic growth in companion animal diagnostics. Net income margin expanded to 25.03% with exceptional ROE of 74.21%, though valuation multiples remain elevated at P/E 41.23.
Outlook remains positive with analyst consensus at 56.5% buy ratings, though premium valuation and competitive pressures present risks. The stock's technical setup suggests potential breakout above $590 resistance could target $609-618 levels, while support at $578-570 provides downside protection. Continued execution on international expansion and diagnostic adoption supports growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Halliburton Company
Halliburton is one of the three largest oilfield service firms in the world, offering superior expertise in a number of business lines, including completion fluids, wireline services, cementing, and countless others. It's the number one pressure pumper in North America, and has been a leading innovator in hydraulic fracturing over the last two decades.
Read more on HAL →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
